Buprenorphine: Clinical and Public Policy Implications (BUPE 2024)
Only learners who have registered and watched the content on https://bupe2024.com/ are eligible to claim credit. All other attempts to claim credit will be deleted.
Claiming Credit
Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete the posttest, evaluation and claim your credit on the following page.
BUPE2024 is a “virtual resource” that is an extension of Journal of Opioid Management’s Special Issue on Buprenorphine. More than a conference, BUPE2024 is a resource for those looking to learn about this interesting molecule. Presentations will be available through August 2025.
Target Audience
Physicians, nurses, pharmacists
Learning Objectives
After participating in this activity, participants should be able to:
- Describe the therapeutic benefits of buprenorphine and highlight indications for its use in acute, chronic, and cancer pain.
- Explain interactions of buprenorphine with other opioids.
- Explain the appropriate application of buprenorphine in pain patients and those with co-morbid substance use disorder.
- Explain the concepts and practice of micro-dosing, rotation, and titration.
- Recognize the legal and regulatory implications of prescribing opioids that arise when treating individuals in pain.
- Explain the basic pharmacology of buprenorphine and utilize and promote evidence-based approaches for clinical treatment.
- Describe the various delivery methods for buprenorphine in the management of pain.
CCE Program Manager - Naomi Moeller
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Weston Medical Publishing . Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Boston University School of Medicine designates this enduring activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists
This activity is approved for 9.25 CPE credit(s) under the ACPE universal activity number UAN JA0000185-9999-24-033-H01-P. The activity is available for credit claiming through 60 days after your participation.
Available Credit
- 9.25 ACPE Pharmacy
- 9.25 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 9.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 9.25 Participation
Only learners who have registered and watched the content on https://bupe2024.com/ are eligible to claim credit. All other attempts to claim credit will be deleted.
Click on the "start course" button on the bottom of the page to start the post test. Follow the red prompts to complete the evaluation and claim your certificate.